Wednesday February 21st 2018

Responsiveness and Clinically Meaningful Improvement, According to Disability Level, of Five Walking Measures After Rehabilitation in Multiple…

Conclusions. Long walking tests and patient-reported MSWS-12 were more appropriate than short walking tests in detecting clinically meaningful improvement after physical rehabilitation, particularly the MSWS-12 for moderate to severely disabled pwMS. (Source: Neurorehabilitation and Neural Repair)

Excerpt from – 

Responsiveness and Clinically Meaningful Improvement, According to Disability Level, of Five Walking Measures After Rehabilitation in Multiple…

Leave a Comment

More from category

MS patients who feel stigmatized more likely to suffer from depression
MS patients who feel stigmatized more likely to suffer from depression

People with Multiple Sclerosis -- MS -- who feel stigmatized are more likely to suffer from depression, according to [Read More]

Stigma increases risk of depression for people with Multiple Sclerosis
Stigma increases risk of depression for people with Multiple Sclerosis

(Penn State) People with Multiple Sclerosis -- MS -- who feel stigmatized are more likely to suffer from depression, [Read More]

Technologies for advanced gait and balance assessments in people with multiple sclerosis – Shanahan CJ, Boonstra FMC, Cofr é Lizama LE, Strik M,…
Technologies for advanced gait and balance assessments in people with multiple sclerosis – Shanahan CJ, Boonstra FMC, Cofr é Lizama LE, Strik M,…

Subtle gait and balance dysfunction is a precursor to loss of mobility in multiple sclerosis (MS). Biomechanical [Read More]

What side effects can result from interferon?
What side effects can result from interferon?

Interferon is used to treat several health conditions, but it has a range of side effects. We look at how these vary in [Read More]

FDA Clears Higher-Dose Glatopa Generic for MS FDA Clears Higher-Dose Glatopa Generic for MS
FDA Clears Higher-Dose Glatopa Generic for MS FDA Clears Higher-Dose Glatopa Generic for MS

Glatopa 40 mg/mL joins already-approved Glatopa 20 mg/mL, a glatiramer acetate generic for treatment of relapsing forms [Read More]